Brolucizumab for Neovascular Age-Related Macular Degeneration (BEL Study)

Brolucizumab for Neovascular Age-Related Macular Degeneration (BEL Study)

Liesbeth Van Cleemput,1,2 Freya Peeters,1,2 Julie Jacob1,2 1Department of Ophthalmology, University Hospital Leuven, Leuven, Belgium; 2Research Group Ophthalmology, Department of Neurosciences, KU Leuven, Leuven, BelgiumCorrespondence: Liesbeth Van Cleemput, Department of Ophthalmology, University H...

Full description

Bibliographic Details
Main Authors:	Van Cleemput L, Peeters F, Jacob J
Format:	Article
Language:	English
Published:	Dove Medical Press 2023-04-01
Series:	Clinical Ophthalmology
Subjects:	macular degeneration vascular endothelial growth factor a intravitreal injections treatment outcome inflammation
Online Access:	https://www.dovepress.com/brolucizumab-for-neovascular-age-related-macular-degeneration-bel-stud-peer-reviewed-fulltext-article-OPTH

Similar Items

Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration
by: Leung EH, et al.
Published: (2023-05-01)

Brolucizumab Intravitreal Injections for Wet Age-Related Macular Degeneration: Real-Life Study on a Cohort of Italian Patients
by: Carlo Gesualdo, et al.
Published: (2023-06-01)

Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab
by: Nudleman E, et al.
Published: (2016-06-01)

Treatment of neovascular age-related macular degeneration within 48 h from diagnosis improves long-term functional outcome
by: Raúl Martínez-Castillo, et al.
Published: (2023-04-01)

Real-World Experience Using Intravitreal Brolucizumab Alone or in Combination with Aflibercept in the Management of Neovascular Age-Related Macular Degeneration
by: Mehta N, et al.
Published: (2023-02-01)

First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration
by: Alaa Din Abdin, et al.
Published: (2022-05-01)

A novel small molecule anti-VEGF drug Brolucizumab in the treatment of neovascular age-related macular degeneration
by: Tong Wu, et al.
Published: (2022-05-01)

Intravitreal injection of Conbercept in the treatment of exudative age-related macular degeneration
by: Hong-Xia Niu, et al.
Published: (2018-09-01)

CFH Y402H polymorphism and response to intravitreal Ranibizumab in brazilian patients with neovascular age-related macular degeneration
by: Carlos Eduardo Veloso, et al.

Assessment of the long-term visual and anatomical outcomes of ranibizumab to treat neovascular age-related macular degeneration
by: Bekir Küçük, et al.
Published: (2018-04-01)

Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study
by: Chakraborty D, et al.
Published: (2021-09-01)

Changes in Scleral Thickness Following Repeated Anti-vascular Endothelial Growth Factor Injections
by: Yao Wang, et al.
Published: (2022-05-01)

Real-World Experience with Brolucizumab in Wet Age-Related Macular Degeneration: The REBA Study
by: Alper Bilgic, et al.
Published: (2021-06-01)

Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects
by: Justus G. Garweg, et al.
Published: (2023-01-01)

The effect of vitreomacular interface in neovascular age-related macular degeneration treated with intravitreal injection of anti-VEGF
by: Fangyuan Han, et al.
Published: (2022-11-01)

Cost-effectiveness of intravitreal therapy in Age-Related Macular Degeneration
by: Piergiorgio Neri, et al.
Published: (2014-12-01)

Intravitreal Brolucizumab in Patients with Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
by: Ashwin Gupta, et al.
Published: (2022-01-01)

Progress in the treatment of neovascular age-related macular degeneration
by: Ya-Xin Wang, et al.
Published: (2021-10-01)

Choroidal structural changes determined by the binarization method after intravitreal aflibercept treatment in neovascular age-related macular degeneration
by: Emine Temel, et al.
Published: (2021-08-01)

A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result
by: Wataru Kikushima, et al.
Published: (2023-04-01)

Intravitreal Aflibercept Treatment Strategies in Routine Clinical Practice of Neovascular Age-Related Macular Degeneration in Belgium: A Retrospective Observational Study
by: Joke Ruys, et al.
Published: (2020-09-01)

Two-Year Follow-Up Study of Patients with Neovascular Age-Related Macular Degeneration Undergoing Anti-VEGF Treatment during the COVID-19 Pandemic
by: Jae-Gon Kim, et al.
Published: (2024-02-01)

Preliminary in vitro and in vivo assessment of a new targeted inhibitor for choroidal neovascularization in age-related macular degeneration
by: Li W, et al.
Published: (2016-10-01)

Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study – Fifty-Two-Week Outcomes
by: Chakraborty D, et al.
Published: (2022-12-01)

Early OCTA Changes of Type 3 Macular Neovascularization Following Brolucizumab Intravitreal Injections
by: Anthony Gigon, et al.
Published: (2022-08-01)

Comparative Effectiveness of Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Managing Neovascular Age-Related Macular Degeneration: A Meta-Analysis
by: Frédéric Matonti, et al.
Published: (2022-03-01)

Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye
by: Emilia Maggio, et al.
Published: (2022-09-01)

Short-Term Outcomes of Faricimab Treatment in Aflibercept-Refractory Eyes with Neovascular Age-Related Macular Degeneration
by: Maya Kishi, et al.
Published: (2023-08-01)

Real-World Frequency and Management of Ocular Adverse Events in Eyes with Neovascular Age-Related Macular Degeneration Treated with Brolucizumab
by: Ryan Zubricky, et al.
Published: (2023-06-01)

Vision Recovery Velocity, Momentum and Acceleration: Advanced Vitreoretinal Analytics as Measure of Treatment Efficacy for Neovascular Age-Related Macular Degeneration
by: Almeida DRP, et al.
Published: (2021-01-01)

Choroidal Effusion following Intravitreal Brolucizumab Injection: A Case Report
by: Ha Eun Sim, et al.
Published: (2022-03-01)

Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration
by: Laura García-Quintanilla, et al.
Published: (2019-07-01)

Short-Term Efficacy and Safety Outcomes of Brolucizumab in the Real-Life Clinical Practice
by: Andrea Montesel, et al.
Published: (2021-11-01)

Interpretation of Consensus on the Optimal Treat-and-Extend Regimen of Neovascular Age-Related Macular Degeneration(2022 Taiwan, China)
by: Bin Wang, et al.
Published: (2022-09-01)

Ten-Year Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration
by: Cheema MR, et al.
Published: (2021-01-01)

Repeated intravitreal injections of antivascular endothelial growth factor in patients with neovascular age-related macular degeneration may increase the risk of ischemic optic neuropathy
by: Yu-Yen Chen, et al.
Published: (2019-12-01)

Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
by: Garweg JG
Published: (2019-07-01)

Lamellar macular hole formation following intravitreal bevacizumab injection for choroidal neovascularization by age-related macular degeneration
by: Hamidreza Torabi, et al.
Published: (2018-01-01)

Synthetic anti-angiogenic genomic therapeutics for treatment of neovascular age-related macular degeneration
by: Jing Wang, et al.
Published: (2021-09-01)

Delaying anti-VEGF therapy during the COVID-19 pandemic: long-term impact on visual outcomes in patients with neovascular age-related macular degeneration
by: Marco Nassisi, et al.
Published: (2023-04-01)